This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.

开始日期2024-11-10

申办/合作机构

Can-Fite BioPharma Ltd.

NCT05201404

/ Recruiting临床3期

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.

开始日期2023-03-15

申办/合作机构

Can-Fite BioPharma Ltd.

NCT04697810

/ Unknown status临床2期

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks. Subjects will be evaluated regularly for safety, and efficacy biomarkers will be measured at Baseline and Weeks 6, 12, 24, and 36. At Week 36, all subjects will undergo liver biopsy.

开始日期2021-12-10

申办/合作机构

Can-Fite BioPharma Ltd.

100 项与 Namodenoson 相关的临床结果

登录后查看更多信息

100 项与 Namodenoson 相关的转化医学

登录后查看更多信息

100 项与 Namodenoson 相关的专利（医药）

登录后查看更多信息

268

项与 Namodenoson 相关的文献（医药）

2026-08-25·CIRCULATION

Endothelial SHMT2 Drives Pulmonary Vascular Remodeling Through Noncanonical Pathway in Pulmonary Hypertension

Article

作者: Yuan, Chong ; Zhao, Yuliang ; Zheng, Tengfei ; Tian, Jingjing ; Wang, Shanshan ; Li, Xiao ; Zhang, Wencheng ; Liu, Dongdong ; Zhang, Cheng ; Zhang, Meng ; Li, Jian ; Wang, Qianqian ; Dai, Shen ; Liu, Xiaolin ; Liu, Fengming ; Zhang, Mei ; Zhao, Yachao ; Zhong, Hongyu ; Pan, Jichen

BACKGROUND::

Pulmonary hypertension (PH) is a progressive, life-threatening disease characterized primarily by pulmonary vascular remodeling in which endothelial dysfunction plays a vital role. However, the molecular factors contributing to this pathological process remain incompletely understood. Through proteomic analysis of hypoxia-treated human pulmonary artery endothelial cells, we identified serine hydroxymethyltransferase 2 (SHMT2) as a potential target in PH, but its role in disease pathogenesis and the underlying mechanisms remain unclear.

METHODS::

The expression and function of SHMT2 were assessed in lung samples from patients with PH and in rodent PH models, including hypoxia-exposed mice and monocrotaline- or Sugen 5416/hypoxia–induced rats. Endothelial cell–specific SHMT2 loss and gain of function were achieved by conditional knockout and adeno-associated virus 9–mediated gene modulation. In vitro studies were performed in hypoxia-treated human pulmonary artery endothelial cells and HEK-293T cells. Virtual screening was used to identify a small-molecule inhibitor targeting the nonmetabolic function of SHMT2, and its therapeutic potential was further evaluated in rodent PH models.

RESULTS::

SHMT2 was upregulated predominantly in pulmonary vascular endothelium of patients with PH and multiple rodent PH models. In vivo, endothelial cell–specific deletion of Shmt2 markedly attenuated pulmonary vascular remodeling and right ventricular dysfunction in PH mice, whereas endothelial cell–specific Shmt2 overexpression aggravated PH development. Consistently, adeno-associated virus 9–mediated endothelial Shmt2 knockdown alleviated PH phenotypes in rat models. Mechanistically, SHMT2 promoted hypoxia-induced endothelial barrier dysfunction mainly through a noncanonical function by blocking the K63-ubiquitin–mediated lysosomal degradation of ras homolog family member B (RhoB). Additional in vivo studies supported an important role of the endothelial SHMT2-RhoB axis in pulmonary vascular remodeling of PH. Through virtual screening, Namodenoson was identified as a small-molecule inhibitor targeting the SHMT2-RhoB pathway. In vivo, Namodenoson showed both preventive and therapeutic effects against PH.

CONCLUSIONS::

This study highlights endothelial SHMT2 as an important contributor to PH pathogenesis and reveals a noncanonical SHMT2-RhoB pathway that promotes endothelial dysfunction. Targeting this pathway may represent a potential therapeutic strategy for PH.

2026-04-01·INTERNATIONAL JOURNAL OF OBESITY

The anti-obesity effect of namodenoson, an A3 adenosine receptor agonist

Article

作者: Amer, Johnny ; Itzhak, Inbal ; Bareket-Samish, Avital ; Safadi, Rifaat ; Salhab, Ahmad ; Fishman, Pnina

Abstract:

Namodenoson—a selective A3 adenosine receptor (A3AR) agonist—is currently in clinical trials for hepatocellular carcinoma and metabolic dysfunction-associated steatotic liver disease. This preclinical study investigated its potential utility as a weight-loss drug. In 3T3-L1 adipocyte cells, namodenoson exhibited a dose-dependent inhibitory effect on the proliferation and accumulation of lipid droplets. Compared to vehicle, 5 and 10 nM of namodenoson inhibited adipocyte proliferation (determined using 3 H-thymidine incorporation assay) by 26 ± 12% ( P < 0.05) and 54 ± 5% ( P < 0.001), respectively, and lipid accumulation (determined by Oil-Red-O staining) by 22 ± 8% ( P < 0.05) and 41 ± 9% ( P < 0.001), respectively. Western blot analyses using 3T3-L1 adipocyte cells demonstrated that namodenoson led to downregulation of A3AR, PPAR γ , C/EBP α , C/EBPβ, p-AKT, PI3K, NF-kB, and β-catenin, and upregulation of adiponectin. In-vivo experiments in a murine model of diet-induced obesity demonstrated that administering daily namodenoson (100 μg/kg) to high-fat-fed mice led to a significant difference in weight after 4 weeks of treatment compared to high-fat-fed mice without namodenoson (44.3 ± 2.2 vs 47.2 ± 3.4 g, respectively, P = 0.001), representing a difference in weight of 6.1%. The same experiment on mice fed a lean diet demonstrated no namodenoson effect (mean weight: 33.5 ± 3.9 vs 33.0 ± 0.6 g, respectively). In conclusion, our findings support continued investigation of namodenoson as a weight-loss drug candidate.

2025-06-01·BIOORGANIC CHEMISTRY

Discovery and characterization of novel FAK inhibitors for breast cancer therapy via hybrid virtual screening, biological evaluation and molecular dynamics simulations

Article

作者: Pan, Youlu ; Huang, Wenhai ; Li, Qin ; Chen, Runmei ; Deng, Yaru ; Yang, Xinle ; Xu, Xiangwei ; Chi, Xinglong ; Chen, Roufen ; Zhou, Peng ; Pan, Zhichao ; Xu, Yingxuan

Focal adhesion kinase (FAK) is a critical drug target implicated in various disease pathways, including hematological malignancies and breast cancer. Therefore, identifying FAK inhibitors with novel scaffolds could offer new opportunities for developing effective therapeutic compounds. Herein, we disclosed the discovery of a new backbone inhibitor of FAK using an "internal" database, employing a structure-based high-transparency permeability virtual screening (HTVS) and a DeepDock algorithm based on geometric deep learning. Subsequently, molecular docking was conducted at different precisions to identify 10 compounds for further evaluation of biological activity. Ultimately, compound 4, a pyrimidin-4-amine derivative, demonstrated inhibitory activity against FAK and breast cancer cells, further supporting its potential as a FAK inhibitor. Moreover, molecular dynamics simulations were carried out to gain more detailed insights into the binding mechanism between compound 4 and FAK to guide subsequent structural optimization.

154

项与 Namodenoson 相关的新闻（医药）

2026-10-03

·雪儿学堂

【2026ESMO】胰腺癌篇章新进展全局观

“ KRAS 从「不可成药」到制药工业最拥挤的赛道，围手术期抑制剂与治疗性疫苗同时推进，胰腺癌的治疗逻辑正在被重写。 —— ESMO 2026 消化道肿瘤摘要解读系列胰腺癌是消化道肿瘤中预后最差的瘤种，也是本届 ESMO 投入最集中的领域之一。我们提取到胰腺癌相关摘要 138 条，体量在六大瘤种中位列第二，其中包含 2 场口头报告、多项 III 期研究和正在进行的一线随机试验。本文把 138 条摘要归为四条战线：KRAS 靶向、免疫与治疗性疫苗、局部治疗强化、化疗策略与真实世界证据，文末附完整清单。 📌 本文看点 01 KRAS G12D 的临床化路径 02 4 项 LBA 密集披露 03 围手术期与局部强化 01 DATA SCAN数据概览：138 条摘要，四大方向同时推进 138 条摘要的形式分布以 Poster 与 ePoster 为主，但看点高度集中在少数重磅研究上：2 场口头报告、4 项 LBA、多项一线 III 期与围手术期研究。中国研究者贡献 30 条摘要，覆盖 KRAS G12D 靶向、真实世界数据与局部治疗。从研究类型看，胰腺癌的方向分化特别明显——一类研究解决「用什么药」，一类解决「什么时候用、联合什么」。 138 胰腺癌相关摘要（条） 2 / 7 口头报告 / 进行中试验 33 中国讲者摘要（条） 129 Poster 与 ePoster 一句话结论：胰腺癌的新药竞争已从化疗骨架的排列组合，转向KRAS 精准靶向与免疫治疗性疫苗。 02 HIGHLIGHTS重磅研究解读本届胰腺癌的口头报告与 4 项 LBA 覆盖了靶向、免疫、局部强化与化疗策略四条主线。 CASE 3137RORapid Oral 新型口服KRAS G12D抑制剂INCB161734联合化疗治疗晚期/转移性胰腺导管腺癌（PDAC）患者的安全性与疗效 Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 讲者：Antoine Hollebecque (Villejuif, France) 新型口服 KRAS G12D 抑制剂 INCB161734 联合化疗的早期数据，是本届口头报告中最受关注的新机制之一。G12D 是胰腺癌最主要的 KRAS 突变亚型，口服小分子的可及性优势，将直接影响这一赛道的落地速度。 CASE LBA82LBA · 优选论文 RAS(ON) 多选择性抑制剂 daraxonrasib 对比化疗用于经治转移性胰腺导管腺癌：III 期 RASolute 302 研究补充亚组分析 Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma: additional subgroup analyses from the Ph3 RASolute 302 study 讲者：Zev A. Wainberg｜洛杉矶，美国 RASolute 302 是 KRAS 抑制剂首次在胰腺癌经治人群中以 III 期形式呈现，本届公布补充亚组分析。「多选择性 RAS(ON) 抑制剂」意味着它不再局限于单一突变亚型，这对突变谱分散的胰腺癌尤为关键。 CASE LBA85LBA · 快速口头报告 HRS-4642 联合化疗±阿得贝利单抗用于 KRAS G12D 突变胰腺癌围手术期治疗：II 期研究初步结果 HRS-4642 plus chemotherapy ± adebrelimab as perioperative therapy in KRAS G12D-mutant pancreatic cancer: preliminary results of a phase 2 study 讲者：沈柏用｜上海交通大学医学院附属瑞金医院国产 KRAS G12D 抑制剂 HRS-4642 直接把适应场景前移到围手术期，并叠加 PD-L1 抗体。这类「靶向+免疫+化疗」的围手术期组合，是本届胰腺癌最具想象力的设计之一。 CASE LBA83LBA · 优选论文七价 mKRAS 特异性淋巴结靶向两亲性免疫治疗对比观察用于已切除胰腺导管腺癌：AMPLIFY-7P 随机 II 期研究 Seven-Valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma: the AMPLIFY-7P randomized phase 2 study 讲者：Eileen M. O’Reilly｜纽约，美国 AMPLIFY-7P 用七价 KRAS 特异性治疗性疫苗挑战术后观察，是免疫治疗在胰腺癌最艰难场景（微小残留病灶）中的一次正面尝试。淋巴结靶向递送技术能否突破胰腺癌的低免疫原性，值得跟踪。 CASE 3136RORapid Oral mFOLFIRINOX±SBRT治疗高危、交界可切除或局部晚期胰腺癌的随机II期研究：AGITG MASTERPLAN试验结果 Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial 讲者：Andrew Oar (Southport, Australia) AGITG MASTERPLAN 研究评估 mFOLFIRINOX±SBRT 用于高危、边缘可切除或局部晚期胰腺癌。SBRT 的加入能否提高可切除转化率，是这项随机 II 期最有临床价值的问题。 CASE LBA84LBA · 快速口头报告一线治疗失败晚期胰腺癌，双药对比单药治疗的随机、多中心、开放标签、双臂 III 期研究（Panc-SELECT——吉西他滨队列） A randomized, multicenter, open-label, double-arm, phase III study of doublet vs monotherapy in advanced pancreatic cancer patients who have failed first-line therapy (Panc-SELECT — gemcitabine arms) 讲者：Prabhat G. Bhargava｜孟买，印度 Panc-SELECT 关注一个很实际的问题：一线失败后，二线到底该用双药还是单药。在体能状态普遍下降的胰腺癌二线人群中，这类研究直接决定临床路径。 CASE 3190TiPTrial in Progress poster setidegrasib联合mFOLFIRINOX或NALIRIFOX一线治疗KRAS G12D突变转移性胰腺导管腺癌（PDAC）的3期双盲随机试验：进行中的试验 A Phase 3, double-blind, randomized trial of setidegrasib + mFOLFIRINOX or NALIRIFOX as first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations: Trial in progress 讲者：Teresa Macarulla Mercade (Barcelona, Spain) setidegrasib 联合 mFOLFIRINOX 或 NALIRIFOX 一线治疗 KRAS G12D 突变胰腺癌的 III 期双盲随机研究。KRAS G12D 抑制剂正式进入一线III期梯队，这是本届胰腺癌在研管线最重要的信号。 CASE 3147PPoster 多药联合化疗对比吉西他滨治疗体弱或老年晚期胰腺癌（MaGPiE）：一项III期随机试验的中期安全性分析 Multi-agent chemotherapy versus gemcitabine in frail or elderly advanced pancreatic cancer (MaGPiE), interim safety analysis of a phase III randomised trial 讲者：Vikas S. Ostwal (Mumbai, India) MaGPiE III 期中期安全性分析：多药联合化疗对比吉西他滨用于体弱或老年晚期胰腺癌。在体能状态受限人群中寻找「减毒而不减效」的方案，比在优势人群中做加法更有现实意义。 03 TRENDS研究方向盘点四条战线各自都有明确的问题清单。 KRAS 靶向：从单亚型到多选择性 INCB161734（3137RO）、daraxonrasib（LBA82）、setidegrasib（3190TiP）、HRS-4642（LBA85）构成完整梯队。从后线到一线、从单药到联合化疗，KRAS 抑制剂的临床化路径已经清晰，接下来比拼的是疗效深度与耐药管理。免疫与治疗性疫苗：从小样本到随机对照 mKRAS 七价疫苗（LBA83）、atebimetinib 联合化疗的一线 III 期（3189TiP）、以及多项免疫联合探索，共同回答「胰腺癌的冷肿瘤属性能否被打破」。局部治疗强化：可切除边界的再定义 mFOLFIRINOX±SBRT（3136RO）与多项新辅助/转化研究，试图用放疗与更强化疗把边缘可切除人群推向 R0 切除。化疗策略与真实世界证据：被低估的部分 Panc-SELECT（LBA84）解决二线双药与单药之争，MaGPiE（3147P）关注老年体弱人群，奥拉帕利维持治疗的真实世界评价（3216eP）则补充了 BRCA 突变人群在临床实践中的表现。 04 FULL LIST完整摘要清单以下为本届 ESMO 胰腺癌相关全部 138 条摘要（中国讲者 30 条），按摘要编号排序。中文题目为 AI 辅助翻译，仅供检索参考。摘要编号作者（讲者）题目（中文 / 英文） 2902P Chao Li (Beijing, China) 基于VHH的抗CLDN18.2 CAR-T疗法IMC002治疗胃/胃食管结合部癌和胰腺癌的I/IIa期试验：持久的缓解与良好的安全性Durable responses with a favorable safety profile in a phase I/IIa trial of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy for gastric/gastroesophageal junction and pancreatic cancers 3012eP Stephen L. Slocum (Daejeon, Republic of Korea) LCB02A：一种靶向Claudin 18.2的ADC，用于治疗胃癌、胰腺癌及其他Claudin 18.2表达肿瘤LCB02A, a Claudin 18.2-directed ADC, for the Treatment of Gastric, Pancreatic, and Other Claudin 18.2-Expressing Cancers 3136RO Andrew Oar (Southport, Australia) mFOLFIRINOX±SBRT治疗高危、交界可切除或局部晚期胰腺癌的随机II期研究：AGITG MASTERPLAN试验结果Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial 3137RO Antoine Hollebecque (Villejuif, France) 新型口服KRAS G12D抑制剂INCB161734联合化疗治疗晚期/转移性胰腺导管腺癌（PDAC）患者的安全性与疗效Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 3138P Shinji Itoh (Fukuoka, Japan) 使用基于全基因组测序的ctDNA检测可切除胰腺癌的分子残留病灶（MRD）：MONSTAR-SCREEN-3的初步发现Molecular Residual Disease Detection for Resectable Pancreas Cancer Using a whole-genome sequencing-based ctDNA assay: Initial findings from the MONSTAR-SCREEN-3 3139P Casper W.F. Van Eijck (Rotterdam, Netherlands) 血浆ctDNA甲基化单倍型图谱作为胰腺导管腺癌FOLFIRINOX方案疗效的预测性生物标志物Plasma ctDNA methylation haplotype profiling as a predictive biomarker for FOLFIRINOX response in pancreatic ductal adenocarcinoma 3140P Dan Zhao (Houston, United States of America) KRAS Q61突变胃肠道恶性肿瘤的等位基因特异性特征及其与胰腺癌临床结局和转录组特征的关系Allele Specific Characteristics of KRASQ61 Mutated Gastrointestinal Malignancies with Clinical Outcomes and Transcriptomic Features in Pancreatic Cancer 3141P Ashish Sharma (New Haven, United States of America) 最大PDAC基因组数据集中种族和民族数据的完全缺失阻碍了对新兴等位基因剂量生物标志物的公平性相关验证：一项数据治理审计Complete absence of race and ethnicity data in the largest PDAC genomic dataset prevents equity-relevant validation of emerging allele dosage biomarkers: a data governance audit 3142P Ashish Sharma (New Haven, United States of America) KRAS等位基因身份和肿瘤突变负荷（TMB）无法区分胰腺导管腺癌中的超常应答者与快速进展者：一项质疑等位基因决定论的阶段匹配极端表型分析KRAS allele identity and tumour mutational burden do not differentiate exceptional responders from rapid progressors in pancreatic ductal adenocarcinoma: a stage-matched extreme-phenotype analysis questioning allele determinism 3143P Christoph Gerdes (Toronto, Canada) 胰腺癌的转录组学重新分类揭示新的分子亚型Transcriptomic Reclassification of Pancreatic Cancer Uncovers Novel Molecular Subtypes 3144P Franck MONNIEN (Besançon, France) 基质HSP47和膜β-catenin作为胰腺导管腺癌辅助化疗获益的预后和预测性生物标志物：模型构建与独立验证Stromal HSP47 and membranous β-catenin as prognostic and predictive biomarkers of adjuvant chemotherapy benefit in pancreatic ductal adenocarcinoma: development and independent validation 3145P Dongsheng Zhang (Guangzhou, China) 维迪西妥单抗（Disitamab Vedotin）治疗HER2表达局部晚期或转移性胰腺癌：一项前瞻性、单臂、II期临床试验Disitamab Vedotin in HER2-Expressing Locally Advanced or Metastatic Pancreatic Cancer: A Prospective, Single-Arm, Phase II Clinical Trial 3146P Vincent Chung (Duarte, United States of America) 仑伐替尼-帕博利珠单抗维持治疗晚期胰腺导管腺癌（PDAC）：II期试验（NCT04887805）结果及免疫相关标志物Lenvatinib-pembrolizumab maintenance therapy in advanced pancreatic ductal adenocarcinoma (PDAC): Phase II trial (NCT04887805) results and immunological correlatives 3147P Vikas S. Ostwal (Mumbai, India) 多药联合化疗对比吉西他滨治疗体弱或老年晚期胰腺癌（MaGPiE）：一项III期随机试验的中期安全性分析Multi-agent chemotherapy versus gemcitabine in frail or elderly advanced pancreatic cancer (MaGPiE), interim safety analysis of a phase III randomised trial 3148P Shinichiro Takahashi (Makinohara, Japan) 新辅助吉西他滨联合白蛋白结合型紫杉醇对比基于S-1的放化疗治疗交界可切除胰腺癌的II/III期试验5年更新（GABARNANCE）5-year update of the phase II/III trial of neoadjuvant gemcitabine plus nab-paclitaxel versus S-1-based chemoradiotherapy for borderline resectable pancreatic cancer (GABARNANCE) 3149P Alexander I. Spira (Fairfax, United States of America) vopimetostat联合daraxonrasib或zoldonrasib治疗MTAP缺失、RAS突变（MTAPdel/RASmut）转移性PDAC和NSCLC患者的1/2期研究A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutated (MTAPdel/RASmut) metastatic PDAC and NSCLC 3150P Dan Cao (Chengdu, China) HRS-4642联合尼妥珠单抗（nimotuzumab）治疗KRAS G12D突变晚期胰腺导管腺癌患者的Ib/II期研究A Phase Ib/II Study of HRS-4642 plus Nimotuzumab in Patients with KRAS G12D-Mutant Advanced Pancreatic Ductal Adenocarcinoma 3151P David J. Pinato (London, United Kingdom) 辅助intismeran autogene联合FOLFIRINOX治疗可切除胰腺导管腺癌：一项I期研究结果Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: results from a phase I study 3152P Teresa Macarulla Mercade (Barcelona, Spain) 与Ibrilatazar联合FOLFIRINOX治疗后转移性胰腺癌结局改善相关的临床相关亚群：来自PanC-ASAP试验的探索性分析Clinically Relevant Subpopulations Associated with Improved Outcomes Following Ibrilatazar Plus FOLFIRINOX in Metastatic Pancreatic Cancer: An Exploratory Analyses from the PanC-ASAP Trial 3153P Salomon M. Stemmer (Petah Tikva, Israel) Namodenoson在晚期胰腺腺癌中实现持久的疾病稳定：一项2a期研究结果Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study 3154P Mette H. Nissen (Herlev, Denmark) 晚期胰腺癌的早期专科姑息治疗（EarlyCarePan）：一项丹麦全国性随机试验Early specialized palliative care in advanced pancreatic cancer (EarlyCarePan): a nationwide Danish randomized trial 3155P Rui Liu (Tianjin, China) QL1706联合西达本胺（chidamide）、白蛋白结合型紫杉醇和吉西他滨一线治疗转移性胰腺癌的疗效与安全性：一项前瞻性、单臂临床试验Efficacy and Safety of QL1706 Combined with Chidamide, Nab-Paclitaxel, and Gemcitabine as First-Line Treatment for Metastatic Pancreatic Cancer: A Prospective, Single-Arm Clinical Trial 3156P Shukui Qin (Nanjing, China) 索凡替尼（surufatinib）联合卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨一线治疗转移性胰腺癌的最终2期分析Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer 3157P Wen-Quan Wang (Shanghai, China) HRS-4642联合双免疫治疗和化疗治疗晚期胰腺癌：一项II期研究第1臂的初步结果HRS-4642 with dual immunotherapy and chemotherapy for advanced pancreatic cancer: Preliminary results from Arm 1 of a phase II study 3158P Huizi Sha (Nanjing, China) 派安普利单抗、安罗替尼与AG化疗联合作为转移性胰腺癌一线方案：一项多中心、随机对照试验（RCT-PAAG）Integrated Penpulimab, Anlotinib and AG Chemotherapy as First-Line Regimen for Metastatic Pancreatic Cancer: A Multi-Centered, Randomized Controlled Trial (RCT-PAAG) 3159P Xiang Kong (Nanjing, China) 脂质体伊立替康（nal-IRI）/5-FU/LV、贝莫苏拜单抗和安罗替尼联合（伴或不伴SBRT）二线治疗转移性胰腺癌：一项II期双队列研究Integrated nal-IRI/5-FU/LV, benmelstobart, and anlotinib with or without SBRT for second-line metastatic pancreatic cancer: A phase II dual-cohort study 3160P Songul Kucukcelebi (Rotterdam, Netherlands) 已切除胰腺癌接受基于树突状细胞的辅助免疫治疗后的长期临床结局和免疫谱分析：REACtiVe-1试验更新结果Long-term clinical outcomes and immune profiling after adjuvant dendritic cell-based immunotherapy in resected pancreatic cancer: updated REACtiVe-1 trial results. 3161P Huikai Li (Tianjin, China) 新辅助依沃西单抗（ivonescimab）联合吉西他滨/白蛋白结合型紫杉醇治疗交界可切除胰腺癌：一项前瞻性单臂II期试验Neoadjuvant ivonescimab plus gemcitabine/nab-paclitaxel for borderline resectable pancreatic cancer: a prospective single-arm phase II trial 3162P Haochen Tang (Nanjing, China) 尼妥珠单抗联合标准辅助化疗用于胰腺癌根治性切除术后：一项前瞻性单臂、双队列II期研究的初步结果Nimotuzumab plus standard adjuvant chemotherapy after curative resection for pancreatic cancer: preliminary results of a prospective single-arm, two-cohort phase II study 3163P Letizia Procaccio (Padua, Italy) PAXG方案对比(m)FOLFIRINOX一线治疗转移性胰腺癌患者：一项多中心目标试验模拟研究PAXG versus (m)FOLFIRINOX as first-line therapy for patients with metastatic pancreatic cancer: a multicenter, target trial emulation study 3164P Janet Graham (Glasgow, United Kingdom) PRIMUS-001：FOLFOX-A（FOLFOX/白蛋白结合型紫杉醇）对比AG（白蛋白结合型紫杉醇/吉西他滨）治疗转移性胰腺癌患者的适应性2期研究，并含生物标志物评估PRIMUS-001: An adaptive phase 2 study of FOLFOX-A (FOLFOX/nab-paclitaxel) versus AG (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic cancer, with biomarker evaluation 3165P Baiyong Shen (Shanghai, China) 围手术期HRS-4642、化疗和阿得贝利单抗治疗KRAS G12D突变胰腺癌：II期初步结果Perioperative HRS-4642, Chemotherapy, and Adebrelimab in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Phase 2 Results 3166P Marc Hilmi (New York, United States of America) 表达骨膜蛋白（POSTN）的胰腺癌相关成纤维细胞（CAFs）定义了与肿瘤侵袭性和治疗反应相关的独特生态位：来自PRODIGE 24试验的证据Periostin (POSTN)-expressing pancreatic cancer-associated fibroblasts (CAFs) define a distinct niche associated with tumor aggressiveness and therapeutic response: evidence from PRODIGE 24 trial 3167P Laura K. Kjær (Herlev, Denmark) 纳武利尤单抗联合伊匹木单抗、TGFβ-15肽疫苗和立体定向体部放疗治疗难治性胰腺癌的I期研究（CheckVAC）Phase I study of nivolumab with ipilimumab combined with TGFβ-15 peptide vaccine and stereotactic body radiotherapy for refractory pancreatic cancer (CheckVAC) 3168P Jialin Li (Shanghai, China) 六周诱导吉西他滨联合白蛋白结合型紫杉醇（AG）后序贯索凡替尼联合AG或单用AG一线治疗局部晚期或转移性胰腺导管腺癌（mPDAC）：一项单中心、双队列II期研究Six Weeks of Induction Gemcitabine Plus Nab Paclitaxel (AG) Followed by Sequential Surufatinib Plus AG or AG alone as First Line Therapy for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): A Single Center, Two Cohort, Phase II Study 3169P Xianjun Yu (Shanghai, China) TQB2868联合白蛋白结合型紫杉醇/吉西他滨±安罗替尼一线治疗转移性胰腺导管腺癌：一项前瞻性多中心双队列II期研究TQB2868 Plus Nab-Paclitaxel/Gemcitabine ± Anlotinib as First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: A Prospective Multicenter Two-Cohort Phase II Study 3170P Noha F. Rashad (Suez, Egypt) OligoPanc共识定义的寡转移胰腺导管腺癌作为预后分层工具对比其他定义标准的价值：一项回顾性验证研究（GI Characterize-PANC-1）The value of OligoPanc consensus definition of Oligometastatic pancreatic ductal adenocarcinoma as a prognostic stratification tool compared to alternative defining criteria: A retrospective validation study (GI Characterize-PANC-1). 3171P Guillaume Ulmann (Saint-Ouen-sur-Seine, France) 已切除胰腺癌营养不良的经济负担：一项全国性卫生经济学研究Economic Burden of Malnutrition in Resected Pancreatic Cancer: A Nationwide Health Economic Study 3172P Rafael Alvarez Gallego (Madrid, Spain) 接受脂质体伊立替康（nal-IRI）治疗的转移性胰腺导管腺癌（mPDAC）患者的长期生存：NALLONG研究与西班牙队列（NALLONG2）的汇总分析Long-term survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI): a pooled analysis of the NALLONG study and a Spanish cohort (NALLONG2) 3173P Ashish Sharma (New Haven, United States of America) KRAS突变拷贝增加与胰腺导管腺癌的转移表现共分离：1157例注释患者中等位基因剂量生物学的新拓展KRAS mutant copy gain co-segregates with metastatic presentation in pancreatic ductal adenocarcinoma: a novel extension of allele dosage biology in 1,157 annotated patients 3174P Antonio Pea (Verona, Italy) 基于病理学的导管内肿瘤相关胰腺癌复发风险模型，用于指导辅助治疗A Pathology-Based Recurrence Risk Model for Intraductal Neoplasm–Associated Pancreatic Carcinoma to Inform Adjuvant Therapy 3175P Giulia Orsi (Milan, Italy) 导管内乳头状黏液性肿瘤（IPMN）来源的胰腺导管腺癌：诊断和治疗意义Intraductal papillary mucinous neoplasm (IPMN)-derived Pancreatic Ductal Adenocarcinoma: diagnostic and therapeutic implications 3176P Minami Nomura (Minato-ku, Japan) SMAD4状态在不可切除胰腺导管腺癌中依赖背景的预后影响Context-dependent prognostic impact of SMAD4 status in unresected pancreatic ductal adenocarcinoma 3177P Marc Hilmi (New York, United States of America) 致病性ATM缺失定义了预后更佳、肝脏趋向性降低且具有独特KRAS-肿瘤微环境（TME）生物学的胰腺癌（PC）Pathogenic ATM loss defines pancreatic cancer (PC) with better prognosis, reduced liver tropism and distinct KRAS-tumor microenvironment (TME) biology 3178P Fieke E. Froeling (Glasgow, United Kingdom) Precision-Panc：英国胰腺癌治疗研发平台的经验与启示（NCT04161417）Precision-Panc: UK therapeutic development platform for pancreatic cancer, experience and lessons learnt (NCT04161417) 3179P Kamal Al-rabi (Amman, Jordan) PDAC的比较基因组图谱：来自中东和全球队列的见解Comparative Genomic Landscape of PDAC: Insights from Middle Eastern and Global Cohorts 3180P Aina De Torner Vidal (Barcelona, Spain) 揭示早发性胰腺癌：来自真实世界队列的临床、分子和治疗见解Unveiling Early-Onset Pancreatic Cancer: clinical, molecular and therapeutic insights from a real-world cohort 3181P Erwan Vo Quang (Paris, France) 免疫检查点抑制剂在MSI-H/dMMR晚期胰腺腺癌中的疗效：一项国际队列的更新分析Efficacy of immune checkpoint inhibitors in MSI-H/dMMR advanced pancreatic adenocarcinoma: updated analysis of an international cohort 3182P Kreina S. Vega Cano (Barcelona, Spain) 根据化疗顺序划分的晚期胰腺导管腺癌（PDAC）真实世界结局Real-world outcomes according to chemotherapy sequencing in advanced pancreatic ductal adenocarcinoma (PDAC) 3183P Morten Karsdal (Herlev, Denmark) 癌症相关成纤维细胞（CAFs）和肿瘤纤维化的液体活检用于评估接受纳武利尤单抗/放疗±伊匹木单抗或吉西他滨/白蛋白结合型紫杉醇±托珠单抗（tocilizumab）治疗的胰腺癌患者的疗效和生存Liquid biopsy of cancer-associated fibroblasts (CAFs) and tumor fibrosis for assessment of response and survival in pancreas cancer patients treated with Nivolumab/radiotherapy ± Ipilimumab or Gemcitabine/Nab-Paclitaxel ± Tocilizumab 3184P Daniel A. King (Lake Success, United States of America) 抗PAUF单克隆抗体PBP1510治疗转移性胰腺腺癌的安全性与疗效Safety and Efficacy of PBP1510, an Anti-PAUF Monoclonal Antibody, in Metastatic Pancreatic Adenocarcinoma 3185P Katherine G. Roth (Duarte, United States of America) PARP抑制剂和铂类化疗改善胰腺腺癌生存，且不依赖于HRD状态PARP inhibitors and Platinum Chemotherapy Improve Survival in Pancreatic Adenocarcinoma Independent of HRD Status 3186TiP Cindy Neuzillet (Boulogne-Billancourt, France) 优化一线NALIRIFOX方案并探索微生物群在胰腺癌二线治疗中的作用：PRODIGE 105 GERCOR PANORAMIX研究Optimizing 1st-line NALIRIFOX and Exploring the Role of Microbiota in 2nd-line Pancreatic Cancer Treatment: The PRODIGE 105 GERCOR PANORAMIX study 3187TiP Maria Pia Morelli (Houston, United States of America) 一项评估Navlimetostat（BMS-986504）联合化疗治疗可切除/交界可切除（队列1）、局部晚期不可切除（队列2）和转移性（队列3）MTAP缺失胰腺癌的II期研究A Phase II Study Evaluating Navlimetostat (BMS-986504) and chemotherapy in resectable/borderline resectable (cohort 1), locally advanced, unresectable (cohort 2), and metastatic (cohort 3) MTAP-deleted Pancreatic Cancer. 3188TiP Do-Youn Oh (Seoul, Republic of Korea) 靶向EphA2的Bicycle药物偶联物（BDC）Nuzefatide Pevedotin治疗转移性胰腺导管腺癌（PDAC）患者的2期研究Phase 2 Study of Nuzefatide Pevedotin, an EphA2-targeting Bicycle Drug Conjugate (BDC), in Patients (Pts) With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 3189TiP Eileen M. O’Reilly (New York, United States of America) 进行中试验——MAPKeeper-301：Atebimetinib联合改良吉西他滨和白蛋白结合型紫杉醇方案对比标准吉西他滨和白蛋白结合型紫杉醇治疗转移性胰腺导管腺癌患者的3期随机、开放标签研究Trial In Progress- MAPKeeper-301: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus Standard Gemcitabine and nab-Paclitaxel for Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma 3190TiP Teresa Macarulla Mercade (Barcelona, Spain) setidegrasib联合mFOLFIRINOX或NALIRIFOX一线治疗KRAS G12D突变转移性胰腺导管腺癌（PDAC）的3期双盲随机试验：进行中的试验A Phase 3, double-blind, randomized trial of setidegrasib + mFOLFIRINOX or NALIRIFOX as first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations: Trial in progress 3191eP Shuai Xiang (Beijing, China) 蛋白质组学驱动的机器学习策略实现新发糖尿病患者胰腺癌的早期检测Proteomic-driven machine learning strategy enables early detection of pancreatic cancer in new-onset diabetes 3192eP Miguel García-Bartolomé (Valencia, Spain) 术后TAV16 ctDNA检测分子残留病灶并预测胰腺癌切除术后复发Postoperative TAV16 ctDNA detects molecular residual disease and predicts relapse after pancreatic cancer resection 3193eP Santiago Sucre (Miami, United States of America) Avutometinib联合defactinib（AvDf）联合或不联合吉西他滨和白蛋白紫杉醇（GnP）治疗既往经治的KRAS突变胰腺导管腺癌（PDAC）患者Avutometinib plus defactinib (AvDf) with or without gemcitabine and nab-Paclitaxel (GnP) in previously treated patients with pancreatic ductal adenocarcinoma (PDAC) harboring KRAS mutations 3194eP Maroua Boujemaa (Tunis, Tunisia) 突尼斯胰腺癌的临床与胚系基因组特征：基因组稳定性及表观遗传通路参与的证据Clinical and Germline Genomic Characterization of Pancreatic Cancer in Tunisia: Evidence for Genome Stability and Epigenetic Pathway Involvement 3195eP Anke Onnekink (Leiden, Netherlands) 携带CDKN2A/p16胚系致病变异个体的胰腺导管腺癌基因组特征Genomic Characterization of Pancreatic Ductal Adenocarcinomas in Individuals with a Germline CDKN2A/p16 Pathogenic Variant 3196eP Carmen Cobos Lama (Madrid, Spain) 杂交捕获二代测序作为PDAC胚系基因组变异筛查工具的应用Hybrid-capture next-generation sequencing as a screening tool for germline genomic alterations in PDAC 3197eP Yung-yeh Su (Tainan City, Taiwan) 胰腺导管腺癌中KRAS突变特异性信号传导与转录程序KRAS Mutation-Specific Signalling and Transcriptomic Programmes in Pancreatic Ductal Adenocarcinoma 3198eP Fengwei Xu (Hang Zhou, China) 靶向PD-L1的ADCplex递送泛KRAS分子胶和伊立替康，在临床前胰腺癌模型中显示出强效抗肿瘤活性且毒性降低PD-L1–Targeted ADCplex Delivering a Pan-KRAS Molecular Glue and Irinotecan Demonstrates Potent Antitumor Activity With Reduced Toxicity in Preclinical Pancreatic Cancer Models 3199eP Shiwei Guo (Shanghai, China) PDAClassify：一种基于甲基化的分类器，用于胰腺导管腺癌的无创分子分型PDAClassify: a methylation-based classifier for non-invasive molecular subtyping of pancreatic ductal adenocarcinoma 3200eP Haripriya Andanamala (Oklahoma City, United States of America) SMAD4和HRD突变决定局限期胰腺癌新辅助化疗的不同应答SMAD4 and HRD Mutations Dictate Divergent Neoadjuvant Chemotherapy Responses in Localized Pancreatic Cancer 3201eP Ujjwal Soni (Oklahoma City, United States of America) 局限期胰腺癌中SMAD4和HRD共突变患者的治疗选择Treatment Selection in Patients with Concurrent SMAD4 and HRD Mutations in Localized Pancreatic Cancer 3202eP Ashish Sharma (New Haven, United States of America) PDAC治疗背景下肿瘤突变负荷解读：FDA阈值仅识别1.3%无预后信号的患者，而更高TMB与化疗患者的不良生存相关Treatment-context-specific tumor mutational burden interpretation in PDAC: the FDA threshold identifies 1.3% of patients without prognostic signal, while higher TMB associates with adverse survival in chemotherapy-treated patients 3203eP Jianfeng Huang (Guangzhou, China) 脾动脉灌注化疗对比全身化疗治疗晚期胰体/尾癌的疗效与安全性：一项真实世界研究Efficacy and Safety of Splenic Artery Infusion Chemotherapy Compared With Systemic Chemotherapy in Advanced Pancreatic Body/Tail Cancer: A Real-World Study 3204eP Aniek E. Van Diepen (Maastricht, Netherlands) 晚期胰腺癌疼痛患病率与强度：一项全国性前瞻性队列研究Pain prevalence and intensity in advanced pancreatic cancer: a nationwide prospective cohort study 3205eP Stefania Gkoura (Athens, Greece) 液体活检检测不可切除胰腺癌RAS突变：与生物标志物、临床参数及肿瘤分子特征的相关性——一项前瞻性观察研究RAS Mutation Detection by Liquid Biopsy in Unresectable Pancreatic Cancer: Correlation with Biomarkers, Clinical Parameters, and Tumor Molecular Features. A Prospective Observational Study 3206eP Deema Al Zoubi (Damascus, Syria) MDCT上肿瘤-血管接触的纵向量化评估作为胰头腺癌血管侵犯及可切除性的预测指标：一项前瞻性研究Longitudinal Tumor–Vessel Contact on MDCT as a Quantitative Predictor of Vascular Invasion and Resectability in Pancreatic Head Adenocarcinoma: A Prospective Study 3207eP David L. Bajor (Cleveland, United States of America) Ivosidenib联合mFOLFIRINOX治疗可切除胰腺导管腺癌（PDA）患者的I期单中心开放标签剂量递减和扩展研究A Phase I, Single-Center, Open-Label, Dose De-escalation and Expansion Study of Ivosidenib Plus mFOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma (PDA) 3208eP Makoto Shinoto (Chiba, Japan) 碳离子放疗治疗不可切除胰腺癌的I期剂量递增研究A phase I dose-escalation study of carbon-ion radiotherapy for unresectable pancreatic cancer 3209eP Juan Du (Nanjing, China) LAPC中NALIRIFOX对比GnP诱导化疗联合PD-1抑制剂序贯SBRT的多中心随机对照II期试验Comparison of NALIRIFOX vs GnP Induction Chemotherapy Combined with PD-1 Inhibitor followed by sequential SBRT in LAPC: A Multi-Center, Randomized Controlled, Phase II Trial 3210eP Seok Jae Huh (Busan, Republic of Korea) 胰腺癌根治性胰切除术后自体自然杀伤细胞辅助治疗联合标准化疗的I期研究延长随访结果Extended follow-up results of a phase I study of adjuvant autologous natural killer cell therapy combined with standard chemotherapy after curative pancreatectomy for pancreatic cancer. 3211eP Kuirong Jiang (Nanjing, China) 脂质体伊立替康联合奥沙利铂及S-1或5-氟尿嘧啶/亚叶酸钙辅助治疗切除术后胰腺导管腺癌：一项多中心随机II期研究Liposomal irinotecan combined with oxaliplatin and S-1 or 5-fluorouracil/leucovorin as adjuvant therapy for resected pancreatic ductal adenocarcinoma: a multicenter randomized phase II study 3212eP Shiwei Guo (Shanghai, China) NALIRIFOX治疗高危可切除胰腺癌：多中心随机开放标签研究NALIRIFOX in high-risk resectable pancreatic cancer: multicenter，randomized, open-label study 3213eP Songul Kucukcelebi (Rotterdam, Netherlands) 立体定向放疗联合IMM-101疫苗治疗少转移性胰腺癌：MEPANC试验的安全性、可行性与免疫调节结果Stereotactic Radiotherapy and IMM-101 Vaccination in Oligometastatic Pancreatic Cancer: Safety, Feasibility, and Immunomodulatory Outcomes of the MEPANC Trial 3214eP Junjie Hang (Changzhou, China) 减剂量短疗程脂质体伊立替康联合卡培他滨二线治疗晚期胰腺癌的疗效与安全性：一项多中心II期研究The Efficacy and Safety of Reduced-dose and Short-course Regimen of Liposomal Irinotecan Plus Capecitabine as Second-Line Therapy for Advanced Pancreatic Cancer: A Multicenter Phase II Study 3215eP Jiujie Cui (Shanghai, China) ALTER-PA-001试验更新结果：安罗替尼联合Benmelstobart加AG方案对比AG方案一线治疗转移性胰腺癌的多中心开放标签随机II期研究Updated Results of the ALTER-PA-001 Trial: A Multicenter, Open-Label, Randomized Phase II Study of Anlotinib Plus Benmelstobart in Combination with AG Versus AG Alone as First-Line Treatment for Metastatic Pancreatic Cancer 3216eP Nono Brano (Chongqing, China) 奥拉帕利维持治疗BRCA突变胰腺导管腺癌的临床评估：来自III期试验、真实世界证据及SEER数据库的见解Clinical Evaluation of Olaparib Maintenance Therapy in BRCA-Mutated Pancreatic Ductal Adenocarcinoma: Insights from Phase III Trials, Real-World Evidence, and the SEER Database 3217eP Giancarlo Del Gaudio (Naples, Italy) 多学科团队管理对临界可切除及局部晚期胰腺癌临床结局的影响：MDT前时代与MDT时代治疗患者的单中心对比研究Impact of Multidisciplinary Team Management on Clinical Outcomes in Borderline Resectable and Locally Advanced Pancreatic Cancer: A Single Center Comparative Study of patient treated in the Pre-MDT and MDT Era 3218eP Daniel Herrero Rivera (Madrid, Spain) 诊断与治疗延误对局限期及转移性胰腺癌的临床影响：一项西班牙多中心回顾性队列研究Clinical impact of diagnostic and treatment delays in localized and metastatic pancreatic cancer: a Spanish multicenter retrospective cohort study 3219eP Joecelyn Kirani Tan (Manchester, United Kingdom) 合并代谢共病胰腺癌死亡率的年龄分层趋势：1999至2020年美国劳动年龄人群的不成比例上升Age-Stratified Trends in Pancreatic Cancer Mortality with Co-occurring Metabolic Comorbidities: A Disproportionate Rise in Working-Age Adults in the United States, 1999 to 2020 3220eP Joecelyn Kirani Tan (Manchester, United Kingdom) 1999至2020年美国合并代谢共病的胰腺癌死亡率的种族与民族模式Racial and Ethnic Patterns in Pancreatic Cancer Mortality with Metabolic Comorbidity Co-occurrence in the United States, 1999 to 2020 3221eP Joecelyn Kirani Tan (Manchester, United Kingdom) 1999至2020年美国合并代谢共病的胰腺癌死亡率的地区及城乡模式Regional and Rural-Urban Patterns in Pancreatic Cancer Mortality with Metabolic Comorbidity Co-occurrence in the United States, 1999 to 2020 3222eP Marta M. Fudalej (Warsaw, Poland) 治疗前全身炎症指数预测胰腺癌患者死亡率的临床应用价值Clinical Utility of Pre-treatment Systemic Inflammation Indices in Predicting Mortality in Pancreatic Cancer Patients 3223eP Chien-Jui Huang (Tainan City, Taiwan) 超越D-二聚体：纤溶酶原激活物抑制剂-1（PAI-1）增强胰腺癌血栓预测及预后分层Beyond D-dimer: Plasminogen activator inhibitor-1 (PAI-1) Enhances Thrombosis Prediction and Prognostic Stratification in Pancreatic Cancer 3224eP Souhaila Akir (Rabat, Morocco) 胰腺癌胆道引流：转移性疾病是否影响ERCP成功率？Biliary Drainage in Pancreatic Cancer: Does Metastatic Disease Influence ERCP Success? 3225eP Sandra Martínez Badal (Barcelona, Spain) 胰腺癌中KRAS相关意义未明变异的功能与定量表征Functional and quantitative characterization of KRAS-associated variants of uncertain significance in pancreatic cancer 3226eP Elena Artamonova (Moscow, Russian Federation) empegfilgrastim一级预防改善转移性胰腺癌（mPC）患者FOLFIRINOX治疗后的相对剂量强度：一项系统综述与匹配调整间接比较（MAIC）结果Primary prophylaxis (PP) with empegfilgrastim improves relative dose intensity after FOLFIRINOX in metastatic pancreatic cancer (mPC) patients: results of a systematic review and matching-adjusted indirect comparison (MAIC) 3227eP Yunok Oh (Seoul, Republic of Korea) 单细胞图谱分析与AI筛选揭示STRA6为克服PDAC间质介导耐药的精准治疗靶点Single-Cell Profiling and AI-Based Screening Reveal STRA6 as a Precision Therapeutic Target to Overcome Stromal-Mediated Resistance in PDAC 3228eP Elizabeth A. Fung (Vancouver, Canada) 胰腺导管腺癌（PDAC）患者代谢共病与胚系致病变异（PGVs）的分析Analysis of metabolic comorbidities in patients with pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) 3229eP Sara Durdiakova (Bratislava, Slovakia) CLDN18.2在胰腺导管腺癌中的表达及临床意义：一项荟萃分析CLDN18.2 Expression and Clinical Significance in Pancreatic Ductal Adenocarcinoma: A Meta-Analysis 3230eP Taehun Kim (Seoul, Republic of Korea) 晚期胰腺癌FOLFIRINOX诱导治疗后的化疗假期：无化疗间期（CFI）时长的可行性及预测因素Chemotherapy Holiday After Induction FOLFIRINOX in Advanced Pancreatic Cancer: Feasibility and Predictors of Chemotherapy-Free Interval (CFI) Length 3231eP Ditila Doracaj (Tirana, Albania) 阿尔巴尼亚胰腺导管腺癌代谢功能障碍的临床病理学关联Clinicopathological associations of metabolic dysfunction in pancreatic ductal adenocarcinoma in Albania 3232eP Yang Liu (Tianjin, China) 晚期胰腺导管腺癌不可逆电穿孔治疗后CA19-9的早期控制Early CA19-9 control after irreversible electroporation in advanced pancreatic ductal adenocarcinoma 3233eP Peter Hosein (Miami, United States of America) ELI-002 7P mKRAS T细胞调节后转移性胰腺癌的根治Eradication of metastatic pancreatic cancer after ELI-002 7P mKRAS T cell modulation 3234eP Bruno Buecher (Paris, France, CEDEX 5) 胰腺导管腺癌多基因Panel检测的法国推荐意见French recommendations on multigene panel testing in pancreatic ductal adenocarcinoma 3235eP Xiaofeng Xue (Suzhou, China) 胰管内支架不能降低临床相关术后胰瘘但增加胰切除术后急性胰腺炎：一项倾向评分匹配分析Internal pancreatic duct stents do not reduce clinically relevant postoperative pancreatic fistula but increase post-pancreatectomy acute pancreatitis: A propensity score-matched analysis 3236eP Xu Pan (Beijing, China) 胰腺导管腺癌的大规模单细胞空间解析Large-Scale Single-Cell Spatial Dissection of Pancreatic Ductal Adenocarcinoma 3237eP Kreina S. Vega Cano (Barcelona, Spain) 晚期胰腺癌（APC）中基于5-氟尿嘧啶（5FU）和吉西他滨（GEM）化疗获益差异的表型特征Phenotypes of differential benefit from 5-fluorouracil (5FU) and gemcitabine (GEM) based chemotherapy in Advanced Pancreatic Cancer (APC) 3238eP Hsin Hui Wang (Taipei City, Taiwan) 靶向TXNDC5重塑促结缔组织增生及代谢微环境并使PDAC对PD-1阻断敏感Targeting TXNDC5 reshapes the desmoplastic and metabolic landscape and sensitizes PDAC to PD-1 blockade 3239eP Daniele Santini (Latina, Italy) 转移性胰腺导管腺癌（mPDAC）的治疗（Tx）策略：来自跨国基于实践与证据的筛查和共识（SCOPE）焦点小组的结果Treatment (Tx) strategies to manage metastatic pancreatic ductal adenocarcinoma (mPDAC): Results from the multinational Screening and COnsensus based on Practices and Evidence (SCOPE) focus groups 3240eP Anika Forstreuter (Hamburg, Germany) 超越BMI：骨骼肌与内脏脂肪作为胰腺癌的独立预后标志物Beyond BMI: skeletal muscle and visceral fat as independent prognostic markers in pancreatic cancer 3241eP Sacha El Khoury (Houston, United States of America) PDAC中CLDN18.2的表达：不依赖KRAS状态及IV期的预后价值CLDN18.2 Expression in PDAC: KRAS Independence and Stage IV Prognostic Value 3242eP Daryna Bulakh (Kaunas, Lithuania) OXTR rs53576基因多态性在胰腺癌中的预后价值Prognostic Value of the OXTR rs53576 gene polymorphism in Pancreatic Cancer 3243eP Hyo Shik Shin (Seoul, Republic of Korea) 肿瘤相关巨噬细胞来源的CXCL16在胰腺导管腺癌中的作用Role of tumor-associated macrophage-derived CXCL16 in pancreatic ductal adenocarcinoma 3244eP Hila Fishman (Haifa, Israel) 肿瘤电场治疗（TTFields）联合FOLFIRINOX或KRAS抑制剂治疗胰腺癌的临床前评估Preclinical evaluation of Tumor Treating Fields (TTFields) with FOLFIRINOX or KRAS inhibition in pancreatic cancer 3245eP Marine Valery (Villejuif, France) 胰腺和肝脏肿瘤加速诊断路径的影响：Gustave Roussy癌症中心多学科胃肠肿瘤团队的经验Impact of an Accelerated Diagnostic Pathway for Pancreatic and Hepatic Tumors: Experience from a Multidisciplinary Gastro-intestinal Oncology team at Gustave Roussy Cancer Center. 3246eP Akhil Deepak Vatvani (Tangerang, Indonesia) 直接口服抗凝药对比低分子肝素用于接受FOLFIRINOX治疗的胰腺腺癌患者：一项倾向评分匹配的真实世界分析Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin in Pancreatic Adenocarcinoma Patients Receiving FOLFIRINOX: A Propensity-Matched Real-World Analysis 3247eP Carol Cremin (Vancouver, Canada) 携带ATM胚系致病变异的胰腺导管腺癌的临床特征与结局：一项回顾性分析Clinical characteristics and outcomes of pancreatic ductal adenocarcinoma with germline pathogenic ATM variants: a retrospective analysis 3248eP Leonardo E. Da Cunha (Sao Jose do Rio Preto, Brazil) FOLFIRINOX对比吉西他滨联合白蛋白紫杉醇一线治疗转移性胰腺癌：真实世界证据的系统综述与荟萃分析First-line FOLFIRINOX versus Gemcitabine plus Nab-Paclitaxel for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Real-World Evidence 3249eP Daniela Iacono (Rome, Italy) 瘤内磷-32微粒（OncoSil®）治疗不可切除局部晚期胰腺腺癌患者的真实世界经验Intratumoral phosphorus-32 microparticles (OncoSil®) in unresectable locally advanced pancreatic adenocarcinoma patients: a real-world experience 3250eP Antoine Jourdain (Paris, France) 胰腺癌确诊时的营养不良、肌少症、高代谢及微量营养素缺乏：NUTRIPAN队列Malnutrition, sarcopenia, hypermetabolism and micronutrient deficiencies at pancreatic cancer diagnosis: the NUTRIPAN cohort 3251eP Ana Paula O. Victorino (Rio de Janeiro, Brazil) 适合序贯治疗的晚期胰腺癌患者的总生存：巴西真实世界数据Overall survival in advanced pancreatic cancer patients eligible for sequential treatment: real-world data from in Brazil 3253eP Navindi De Silva (Vancouver, Canada) 标准与改良吉西他滨/白蛋白紫杉醇给药方案在转移性胰腺癌中的真实世界生存结局Real-World Survival Outcomes Associated with Standard Versus Modified Gemcitabine/Nab-Paclitaxel Dosing Schedules in Metastatic Pancreatic Cancer 3254eP Ana Paula O. Victorino (Rio de Janeiro, Brazil) 晚期胰腺癌的治疗机会丧失：巴西真实世界队列中的早期死亡模式、基线危险因素及快速进展者特征Treatment opportunity loss in advanced pancreatic cancer: early mortality patterns, baseline risk factors, and characterization of rapid progressors in a brazilian real-world cohort 3255eP Jesus Rodriguez Pascual (Madrid, Spain) 晚期胰腺癌的治疗顺序安排：一项大规模真实世界分析Treatment sequencing in advanced pancreatic cancer: a large real-world analysis 3256eP Joecelyn Kirani Tan (Manchester, United Kingdom) 美国合并代谢共病的胰腺癌死亡率二十年全国趋势：一项基于人群的横断面分析（1999–2020）Two-Decade National Trends in Pancreatic Cancer Mortality with Metabolic Comorbidities in the United States: A Population-Based Cross-Sectional Analysis (1999–2020) 3257eP Diyora Kurambaeva (Tashkent, Uzbekistan) 胰腺癌手术根治性的个体化把握：标准切除与解剖靶向切除的荟萃分析与系统综述Tailoring Surgical Radicality in Pancreatic Cancer: A Meta-Analysis and Systematic Review of Standard versus Anatomically Targeted Resections 3258eP Sergio Perez-Fernandez (Barcelona, Spain) 胰腺导管腺癌根治性切除术后复发的多维分析Multidimensional analysis of recurrence after curative-intent resection of pancreatic ductal adenocarcinoma. 3259eP Maryam Taherioun Isfahani (Tehran, Iran) 临界可切除或局部晚期胰腺导管腺癌新辅助治疗后的手术时机：系统综述与荟萃分析Surgical Timing After Neoadjuvant Therapy in Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis 3260eP Patricia Capdevila Gaudens (Valencia, Spain) 从临界可切除到可切除：胰腺腺癌新辅助治疗后谁真正接受了手术From borderline to resectable: who truly reaches surgery after neoadjuvant therapy for pancreatic adenocarcinoma 3261eP Blanca María Fernández Bellón (Madrid, Spain) 光子计数探测器CT用于胰腺肿瘤：诊断准确性、图像质量及辐射剂量的系统综述与荟萃分析Photon-counting detector CT for pancreatic neoplasms: a systematic review and meta-analysis of diagnostic accuracy, image quality, and radiation dose 3262eP Yasmin B. Da Cruz (Curitiba, Brazil) 非转移性胰腺导管腺癌根治性手术的利用不足：来自SEER分析的社会经济与种族决定因素Underutilization of Curative-Intent Surgery in Non-Metastatic Pancreatic Ductal Adenocarcinoma: Socioeconomic and Racial Determinants from a SEER Analysis 3263eP Xiaofei Zhang (Shanghai, China) 戈沙妥珠单抗治疗多线经治晚期胰腺癌的预后因素与安全性Prognostic factors and safety of sacituzumab govitecan in heavily pretreated advanced pancreatic cancer 3264eP Xuyao Zhang (Shanghai, China) 靶向PD-1和IL-18R的三特异性抗体在胰腺癌中以更优安全性增强抗肿瘤免疫Trispecific Antibody Targeting PD-1 and IL-18R Enhances Antitumor Immunity with Superior Safety Profile in Pancreatic Cancer 3265eP Burak Alper Zengin (Istanbul, Türkiye) 早发转移性胰腺癌的临床特征与生存结局Clinical Characteristics and Survival Outcomes in Early-Onset Metastatic Pancreatic Cancer 3266eP Ravi Kumar Paluri (Winston-Salem, United States of America) 循环microRNA纵向动态变化作为胰腺癌诱导化疗联合SBRT治疗后应答及生存的探索性预测指标Longitudinal circulating microRNA dynamics as exploratory predictors of response and survival in pancreatic cancer treated with induction chemotherapy followed by SBRT 3267eP Alihan Altunay (Antalya, Türkiye) 临界可切除胰腺癌的新辅助化疗：临床结局及其与CT肿瘤密度的关联Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer: Clinical Outcomes and association with CT Tumor Density 3268eP Sehyun Park (Szeged, Hungary) 微创对比开放胰切除术治疗可切除胰腺导管腺癌的肿瘤学结局：系统综述与荟萃分析Oncologic Outcomes of Minimally Invasive Versus Open Pancreatectomy for Resectable Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis 3269eP Mutiu Jimoh (Lagos, Nigeria) 私立医疗机构中的胰腺癌：尼日利亚拉各斯的治疗与生存结局——十年回顾Pancreatic Cancer in Private Care: Treatment _ Survival Outcomes from Lagos, Nigeria – A 10-Year Review 3270eP Jiayue Zou (Suzhou, China) 术前活化部分凝血活酶时间作为初始切除胰腺导管腺癌早期复发及生存的独立预测因子Preoperative activated partial thromboplastin time as an independent predictor of early recurrence and survival in upfront resected pancreatic ductal adenocarcinoma 3272eTiP Haiqi Lu (Hangzhou, China) 优替德隆注射液治疗标准治疗难治的晚期胰腺癌的单臂探索性临床试验A single-arm exploratory clinical trial of Utidelone injection for advanced pancreatic cancer refractory to standard therapy 3273eTiP Einar Sulheim (Oslo, Norway) PS101声学簇疗法联合化疗治疗局部晚期胰腺癌（ENACT试验）PS101 in Acoustic Cluster Therapy with Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer (ENACT trial) ∞ EPILOGUE写在最后胰腺癌是本届 ESMO 变化最剧烈的瘤种：三年前 KRAS 还只是转化研究的题目，如今已经有 III 期、有围手术期设计、有疫苗平台。但也要保持清醒——胰腺癌的临床决策仍然高度依赖体能状态与营养支持，新药能否真正改变生存曲线，还要看随后的 III 期读出。「KRAS 之后，胰腺癌需要的是能进入一线、进入围手术期的完整证据链，而不只是漂亮的早期缓解率。」 END 本文数据整理自 ESMO Congress 2026 官方公开日程（含 LBA 及专场报道），中文题目为 AI 辅助翻译，仅供检索参考，请以英文原文为准。如果你觉得今天这篇有收获，欢迎点赞、在看、转发三连，See You！扫码关注我，上学堂呦版权声明：本平台旨在帮助医疗卫生专业人士更好地了解相关疾病领域最新进展。本平台对发布的资讯内容，并不代表同意其描述和观点，仅为提供更多信息。如该等信息被用于了解资讯以外的目的，本平台及作者不承担相关责任。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。仅供医疗卫生专业人士为了解资讯使用，该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。

2026-09-09

·BioSpace

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the publication of a peer-reviewed case report describing the clinical course of a patient with advanced decompensated liver cirrhosis treated with Namodenoson. During treatment, the patient experienced resolution of ascites and regression of esophageal varices. The article, titled “ Namodenoson Treatment in Decompensated Cirrhosis: Hemodynamic–Clinical Improvement Enabling Bridging to Liver Transplantation ” was published in the Japanese Journal of Gastroenterology and Hepatology (Link). During Namodenoson treatment, ascites resolved, allowing discontinuation of diuretic therapy, while follow-up endoscopy showed only minimal residual esophageal varices. Notably, these clinical improvements occurred despite continued deterioration in hepatic synthetic function. After approximately 28 months of Namodenoson treatment, the patient underwent successful orthotopic liver transplantation from a deceased donor in January 2026, with a favorable post-transplant recovery. “Patients with decompensated cirrhosis have very limited therapeutic options, and liver transplantation remains the only definitive treatment,” said Prof. Ohad Etzion, M.D., Director of the Department of Gastroenterology and Liver Diseases at Soroka University Medical Center, Beer-Sheva, Israel, who treated the patient. “This case is particularly interesting because the improvement in clinically important complications of portal hypertension occurred despite continued deterioration in underlying liver function. The patient remained clinically stable for approximately 28 months and was successfully bridged to liver transplantation. While this is a single-patient observation, the findings support further evaluation of Namodenoson as a potential therapeutic approach in advanced liver disease.” Namodenoson is a highly selective agonist of the A3 adenosine receptor (A3AR), which is highly expressed in inflammatory and pathological cells. Activation of A3AR has been reported to exert anti-inflammatory and anti-fibrotic effects, including through modulation of NF-κB and Wnt/β-catenin signaling pathways. Namodenoson has demonstrated activity in preclinical and clinical studies in liver diseases, including metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma in patients with underlying cirrhosis. About Namodenoson Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and is enrolling patients in a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety pro the drug. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological, inflammatory, and metabolic diseases. The Company’s lead drug candidate, Piclidenoson, is currently being evaluated in a pivotal Phase III study for the treatment of psoriasis. Can-Fite’s oncology and liver drug candidate, Namodenoson, is being evaluated in a pivotal Phase III study for the treatment of hepatocellular carcinoma (HCC) and in a Phase IIb study for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Namodenoson has also demonstrated encouraging clinical activity in a Phase IIa study in patients with advanced pancreatic cancer, supporting its further clinical development in this indication. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation by the U.S. Food and Drug Administration as a second-line treatment for HCC. In addition, Namodenoson has demonstrated potential in other oncological indications, while preclinical and clinical findings support the broader therapeutic potential of Can-Fite’s A3 adenosine receptor platform. CF602, the Company’s third drug candidate, has demonstrated preclinical efficacy in the treatment of erectile dysfunction. Can-Fite’s drug candidates have demonstrated a favorable safety pro clinical studies involving more than 1,700 patients to date. For more information, please visit Can-Fite’s website: . Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 26, 2026 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Can-Fite BioPharma Motti Farbstein info@canfite.com +972-3-9241114

临床2期临床结果快速通道孤儿药

2026-09-08

·BioSpace

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for H1 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes. The open-label Phase IIa study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following standard therapies. Fourteen patients received Namodenoson as third-line treatment, five as second-line treatment, and one as fourth-line treatment. Namodenoson was well tolerated. Overall survival findings identify a subset of heavily pretreated pancreatic cancer patients achieving prolonged survival despite receiving Namodenoson as third-line therapy. A Phase IIb study protocol which combines chemotherapy and Namodenoson is under development. An abstract highlighting the positive results has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026. Hepatocellular Carcinoma (HCC) Blinded overall survival observed across the entire patient population in the Company’s ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma (HCC) appears longer than originally anticipated based on the assumptions underlying the study design. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); In view of the longer-than-anticipated survival observed in the study population, Can-Fite is evaluating an earlier timing for the study’s planned interim analysis. Clinical Progress in Psoriasis The Company completed enrolment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. The study has now reached the pre-specified interim analysis stage under a protocol agreed with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The interim analysis will evaluate efficacy and safety data from the enrolled patients. Results are expected during Q1 2027 . Strengthening of Intellectual Property Portfolio Can-Fite continued to expand its global intellectual property estate with multiple patent allowances across key territories, including Israel, Canada, Brazil, Australia and Japan, covering novel therapeutic uses of Namodenoson and Piclidenoson. These additions further strengthen the Company’s long-term commercial positioning and pipeline value. Motti Farbstein Can-Fite’s CEO&CFO stated: “The first half of 2026 was marked by meaningful progress across our clinical programs. We are particularly encouraged by the longer-than-anticipated overall survival observed to date in our ongoing pivotal Phase III liver cancer study, while recognizing that the study remains blinded. In parallel, the durable survival outcomes observed in heavily pretreated pancreatic cancer patients and the advancement of our pivotal psoriasis study to its interim analysis stage further strengthen our clinical pipeline. We remain focused on disciplined execution of these late-stage programs and on advancing Namodenoson and Piclidenoson toward important clinical and regulatory milestones.” ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); Financial Results Revenues Revenues for the six months ended June 30, 2026 were $0.20 million compared to $0.20 million for the six months ended June 30, 2025. Revenues for the six months ended June 30, 2026 and for the six months ended June 30, 2026 comprise of a portion of advance payments received under our existing out-licensing agreements with Cipher, CKD Gebro and Ewopharma. Research and development expenses ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); Research and development expenses for the six months ended June 30, 2026 were $3.45 million, an increase of $0.42 million, or 13.86%, compared to $3.03 million for the six months ended June 30, 2025. Research and development expenses for the first half of 2026 comprised primarily of expenses associated with the ongoing of the Phase 3 study of Piclidenoson for the treatment of psoriasis and two ongoing studies for Namodenoson, a Phase 3 study in the treatment of advanced liver cancer and a Phase 2b study for MASH. The increase is primarily due to acceleration in expenses associated with both the Namodenoson and Piclidenoson programs. General and administrative expenses General and administrative expenses for the six months ended June 30, 2026 were $1.42 million, a decrease of $0.65 million, or 31.40%, compared to $2.07 million for the six months ended June 30, 2025. The decrease is primarily due to lower investors relations expenses. We expect that general and administrative expenses will remain at the same level through 2026. Financial income, net ezstandalone.cmd.push(function () { ezstandalone.showAds(134); }); Financial income, net for the six months ended June 30, 2026 was $0.08 million compared to $0.02 million for the six months ended June 30, 2025. The increase in financial income, net was mainly due to higher interest income from bank deposits. Net loss for the six months period ended June 30, 2026 was $4.60 million compared with a net loss of $4.87 million for the six months period ended June 30, 2025 . The decrease in net loss for the six months period ended June 30, 2026 was primarily attributable to a decrease in general and administrative expenses which was offset by an increase in research and development expenses . As of June 30, 2026, Can-Fite had cash and cash equivalents and short term deposits of $7.03 million as compared to $8.53 million at December 31, 2025. The decrease in cash during the six months period ended June 30, 2026 is mainly due to the Company's operating loss which was offset by proceeds from issuance of shares and warrants. During September 2026, the Company received aggregate gross proceeds of approximately $4.0 million from warrant exercises and a warrant inducement. The Company's consolidated financial results for the six months period ended June 30, 2026 are presented in accordance with US GAAP Reporting Standards. ezstandalone.cmd.push(function () { ezstandalone.showAds(135); }); CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (except for share and per share data) June 30, December 31, 2026 2025 Unaudited ASSETS CURRENT ASSETS: Cash and cash equivalents $ 2,985 $ 5,528 Short term deposits 4,052 3,011 Prepaid expenses and other current assets 960 900 Short-term investment 6 1 Total current assets 8,003 9,440 NON-CURRENT ASSETS: Operating lease right of use assets 47 69 Property, plant and equipment, net 5 5 Total non-current assets 52 74 Total assets $ 8,055 $ 9,514 CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (except for share and per share data) June 30, December 31, 2026 2025 Unaudited LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES: Trade payables $ 681 $ 1,161 Current maturity of operating lease liability 48 56 Deferred revenues 405 405 Other accounts payable 1,091 1,109 Total current liabilities 2,225 2,731 NON-CURRENT LIABILITIES: Long - term operating lease liability 1 15 Deferred revenues 974 1,176 Total long-term liabilities 975 1,191 CONTINGENT LIABILITIES AND COMMITMENTS SHAREHOLDERS’ EQUITY: Ordinary shares of no-par value - Authorized: 30,000,000 and 14,000,000 shares at June 30, 2026 and December 31, 2025, respectively; Issued and outstanding: 4,285,093 and 2,618,425 shares as of June 30, 2026 and December 31, 2025, respectively - - Additional paid-in capital 184,518 180,654 Accumulated other comprehensive income 1,127 1,127 Accumulated deficit (180,790 ) (176,189 ) Total shareholders’ equity 4,855 5,592 Total liabilities and shareholders’ equity $ 8,055 $ 9,514 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS U.S. dollars in thousands (except for share and per share data) Six months ended June 30, 2026 2025 Unaudited Revenues $ 202 $ 202 Research and development expenses (3,456 ) (3,034 ) General and administrative expenses (1,426 ) (2,066 ) Operating loss (4,680 ) (4,898 ) Financial income, net 79 22 Operating loss (4,601 ) (4,876 ) Basic and diluted net loss per share (1.24 ) (4.29 ) Weighted average number of ordinary shares used in computing basic and diluted net loss per share 3,711,018 1,137,303 About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite's cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of steatotic liver disease (SLD), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety pro experience in over 1,600 patients in clinical studies to date. For more information please visit: . Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to the security situation in Israel; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 26, 2026 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Can-Fite BioPharma Motti Farbstein info@canfite.com +972-3-9241114

临床结果临床2期孤儿药财报临床3期

100 项与 Namodenoson 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11128	-	-	DB12885

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期肝细胞癌	临床3期	美国	Can-Fite BioPharma Ltd.	2023-03-15
晚期肝细胞癌	临床3期	波斯尼亚和黑塞哥维那	Can-Fite BioPharma Ltd.	2023-03-15
晚期肝细胞癌	临床3期	保加利亚	Can-Fite BioPharma Ltd.	2023-03-15
晚期肝细胞癌	临床3期	以色列	Can-Fite BioPharma Ltd.	2023-03-15
晚期肝细胞癌	临床3期	摩尔多瓦	Can-Fite BioPharma Ltd.	2023-03-15
晚期肝细胞癌	临床3期	波兰	Can-Fite BioPharma Ltd.	2023-03-15
晚期肝细胞癌	临床3期	罗马尼亚	Can-Fite BioPharma Ltd.	2023-03-15
晚期肝细胞癌	临床3期	塞尔维亚	Can-Fite BioPharma Ltd.	2023-03-15
晚期肝细胞癌	临床3期	斯洛伐克	Can-Fite BioPharma Ltd.	2023-03-15
纤维化	临床3期	美国	Can-Fite BioPharma Ltd.	2023-03-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06387342 (ESMO2026)	临床2期	晚期胰腺腺癌	20	Namodenoson 25 mg	選網襯選鬱鏇鬱選醖膚(窪夢壓鬱築鹽簾選夢簾) = Namodenoson demonstrated a favorable safety and tolerability profile consistent with prior reports with no new safety signals. 繭構鹹選襯糧鏇鹽齋憲 (鹽襯鬱願鹽憲網膚構齋 )	积极	2026-10-23
GlobeNewswire 人工标引	N/A	失代偿性肝硬化	1	Namodenoson	壓鏇遞觸製鏇壓顧製淵(艱選廠憲簾顧鹽構鏇餘) = The patient, previously reported by Can-Fite to have experienced the disappearance of end-stage liver disease complications while receiving Namodenoson, has now demonstrated a complete resolution of esophageal varices, as confirmed by endoscopic evaluation. 築鬱鹹鏇鹹鬱築願鏇膚 (選淵觸蓋獵簾憲鏇築鑰 )	积极	2025-09-15
Company_Website 人工标引	N/A	失代偿性肝硬化	-	Namodenoson	餘獵積衊衊繭淵醖齋廠(窪衊選觸觸餘襯夢願艱) = At 20 months into treatment, the patient reports notable improvements in symptoms related to the disease, such as fatigue and edema. Prior to starting Namodenoson, the patient had experienced an episode of esophageal variceal bleeding, but no further gastrointestinal bleeding episodes have occurred since beginning therapy. Additionally, moderate ascites that were present before treatment have gradually resolved, with the patient now off diuretics for over a year. Liver stiffness, measured repeatedly during the course of treatment, shows a mean decline compared to levels recorded before therapy began. Importantly, elevated globulin levels – a marker of advanced liver disease – have also started to decrease. 蓋襯壓壓選鹹繭繭膚蓋 (獵積廠繭顧衊鏇鑰構築 )	积极	2025-02-18
Can-Fite (GlobeNewswire) 人工标引	临床2期	肝癌	1	Namodenoson	齋憲醖顧蓋積窪鹹襯壓(觸衊遞壓餘觸艱遞鑰築) = 鏇獵繭構夢夢憲遞選衊網構觸遞淵衊醖繭網窪 (製築顧網壓醖窪廠築鹽 )	积极	2024-12-04
NCT02128958 (ASCO_Breakthrough2023)	临床2期	晚期肝细胞癌二线	78	Namodenoson	繭網繭繭鑰範衊繭範遞(壓廠淵衊積壓積壓積艱) = 獵醖蓋蓋艱糧顧餘顧網築夢衊鹹選簾壓遞艱顧 (鏇壓鏇憲遞鹽壓製觸顧 ) 更多	积极	2023-08-03
				Placebo	繭網繭繭鑰範衊繭範遞(壓廠淵衊積壓積壓積艱) = 廠鬱遞觸鹹壓壓顧鏇衊築夢衊鹹選簾壓遞艱顧 (鏇壓鏇憲遞鹽壓製觸顧 ) 更多
NCT02128958 (ILCA2022)	临床2期	晚期肝细胞癌	-	Namodenoson	顧積夢觸艱鬱築積顧蓋(齋築夢網衊願壓構網鹹) = 醖鹽願觸衊繭選醖憲觸醖鬱憲淵觸餘觸鏇襯鹹 (築鑰糧糧築選顧襯簾繭 ) 更多	积极	2022-09-02
				Placebo	顧積夢觸艱鬱築積顧蓋(齋築夢網衊願壓構網鹹) = 繭範鑰廠糧餘築構範鑰醖鬱憲淵觸餘觸鏇襯鹹 (築鑰糧糧築選顧襯簾繭 )
NCT02128958 (CTgov)	临床2期	纤维化 \| 晚期肝细胞癌	78	CF102 (CF102)	糧膚獵膚遞夢構膚顧齋 = 廠網繭憲選艱製顧淵夢鹹鬱餘壓範齋窪窪製醖 (鑰積艱範鹽衊夢膚淵醖, 積蓋製範淵淵製鹽鑰蓋 ~ 鑰齋選願糧築糧襯蓋壓) 更多	-	2021-12-29
				Placebo (Placebo Tablets of CF102)	糧膚獵膚遞夢構膚顧齋 = 艱蓋淵廠膚鏇襯網願餘鹹鬱餘壓範齋窪窪製醖 (鑰積艱範鹽衊夢膚淵醖, 襯網襯艱鏇壓鏇製窪範 ~ 廠構網觸壓鬱範網艱淵) 更多
NCT02927314 (Pubmed \| Aliment Pharmacol Ther)	临床2期	脂肪肝 \| 代谢功能障碍相关的脂肪肝病	60	Namodenoson 25 mg b.d.	顧艱製窪糧餘廠鑰淵構(窪襯網觸願願範鹹觸鬱) = 網齋築繭醖選製鏇築選積構夢網築鬱憲壓鏇鬱 (醖築膚鏇膚廠夢顧簾鹽 )	-	2021-10-20
				Placebo	顧艱製窪糧餘廠鑰淵構(窪襯網觸願願範鹹觸鬱) = 齋衊簾襯醖膚構願鬱簾積構夢網築鬱憲壓鏇鬱 (醖築膚鏇膚廠夢顧簾鹽 )
NCT02128958 (Pubmed) 人工标引	临床2期	纤维化 \| 晚期肝细胞癌二线	78	Namodenoson	鹽觸積築壓鏇築願鏇廠(顧顧齋簾醖醖範繭繭廠) = 鬱衊選製網獵衊鑰糧淵鏇鏇範廠膚膚鹹鏇獵憲 (繭壓壓願願繭遞夢廠網 ) 更多	积极	2021-01-07
				Placebo	鹽觸積築壓鏇築願鏇廠(顧顧齋簾醖醖範繭繭廠) = 夢鏇網顧築顧網艱淵鹽鏇鏇範廠膚膚鹹鏇獵憲 (繭壓壓願願繭遞夢廠網 ) 更多
NCT02128958 (ASCO 12019 \| ASCO 22019) 人工标引	临床2期	晚期肝细胞癌二线	78	Namodenoson 25 mg	觸夢構襯積簾鹹蓋遞鑰(簾廠蓋網鬱齋襯襯餘範) = 鏇壓醖顧簾獵鬱鏇憲顧夢願膚簾願餘鹹蓋遞餘 (襯遞範鹽簾繭鹹鹹窪獵 )	积极	2019-06-02
				placebo	觸夢構襯積簾鹹蓋遞鑰(簾廠蓋網鬱齋襯襯餘範) = 齋衊衊艱淵製顧鑰夢鏇夢願膚簾願餘鹹蓋遞餘 (襯遞範鹽簾繭鹹鹹窪獵 )